89Bio Is A Clinical Stage Biopharmaceutical Company Based In San Franciscocaliforniawith A Satellite Office In Rehovotisraelthe Company Is Focused On Developing Innovative Therapies For Patients With Liver And Cardiometabolic Diseasestheir Primary Areas Of Interest Include Metabolic Dysfunction Associated Steatohepatitismashand Severe Hypertriglyceridemiashtg A Key Product In Their Pipeline Is Pegozaferminwhich Is Undergoing Pivotal Trials And Is Noted For Its Potential Benefits In Fibrosis And Safety 89Bio Is Committed To Creating Best In Class Therapies And Is Actively Engaged In Clinical Trials And Regulatory Preparationsincluding A Biologics License Applicationbla The Company Has A Strong Financial Positionwith $440 Million In Cash As Of December 312024Additionally89Bio Is Recognized For Its Positive Work Environmentwith A High Employee Satisfaction Ratemaking It A Desirable Workplace For Its Staff
